Lonza’s Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next‑Generation Bispecific ADCs
Multi-target license agreement grants Sidewinder access to Lonza’s clinically validated ADC platform Sidewinder’s pipeline of precision bispecific ADCs combined with Lonza’s clinically validated ADC platform will enable the development of first-in-class bispecific ADCs with enhanced tumor-cell internalization to treat solid tumor indications Amsterdam, The Netherlands, and San Diego, CA, 7 January 2026 — Synaffix B.V. […]
